BF Biosciences Launches CGM Devices in Pakistan
Summary
BF Biosciences, in collaboration with SIBIONICS, launches Sibionics CGM devices in Pakistan, enhancing diabetes management solutions.
Kind of disclosure: Product launch
Read the original filingKey facts
- Launch of Sibionics CGM devices
- Collaboration with SIBIONICS
- Product launch location
- Pakistan
- Collaboration with SIBIONICS
- Global presence in CGM technology
BF Biosciences Limited (BFBIO) on Nafa
Last price Rs 135.48 · Pharmaceuticals · You can own BFBIO shares from your phone.
More BFBIO announcements
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30-09-2026
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeAnnual Progress Report for the Year Ended June 30, 2026
- Financial resultBF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026Filed as: Financial Results for the Quarter Ended 30-09-2026
- NoticeBoard Meeting
- NoticeTransmission of Annual Financial Statements for the Year Ended 30-06-2026
Source: BF Biosciences Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.